Differentiating Bispecific Administration Between Institutions for Multiple Myeloma
A panel of experts discussed their institutions’ practices for administering bispecific antibodies, BCMA or GPRC5D, to patients with multiple myeloma.
Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL
CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.
